The global Hypoventilation Management Market Size is estimated to achieve an amazing valuation of US$ 7.1 billion in 2023 and reach US$ 11.9 billion by 2033, growing at a 5.3% CAGR during the forecast period. Obesity may be on the rise as high-calorie foods become more popular and widely available among young people. This, in turn, causes a variety of diseases such as sleep difficulties. This is a critical factor driving the market expansion of hypoventilation diagnostic equipment. The use of sleep diagnostic gadgets will aid in the early detection of the problem. As a result, this aspect is regarded as one of the key drivers of the expansion of hypoventilation diagnostic equipment.
The Hypoventilation Management market refers to the healthcare sector involved in the diagnosis, treatment, and management of patients suffering from hypoventilation syndrome. Hypoventilation syndrome is a condition characterized by inadequate ventilation, resulting in increased levels of carbon dioxide and decreased levels of oxygen in the blood. This condition can be caused by various factors, including respiratory muscle weakness, central nervous system disorders, and obesity. The Hypoventilation Management market encompasses a range of medical devices, therapies, and interventions aimed at improving ventilation and optimizing respiratory function in affected individuals.
Discover the Impact of Rising Investments in Hypoventilation Management Market – Download Our Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16517
The Hypoventilation Management market has witnessed significant growth in recent years, driven by the rising prevalence of respiratory disorders and an aging population. Advancements in technology have led to the development of innovative devices and therapies, such as non-invasive ventilation (NIV) systems, which have revolutionized the management of hypoventilation. Additionally, increased awareness about the importance of early diagnosis and treatment of hypoventilation syndrome has further fueled market growth. With ongoing research and development activities in this field, the Hypoventilation Management market is expected to expand in the coming years, providing better options for patients and healthcare providers to effectively manage this condition.
Key Takeaways from the Market Study
- North America is expected to dominate the industry while reaching a market share of around 41% by end of the forecast period.
- The market in South Asia is projected to reflect a CAGR of 5.5% during the projected timeline.
- By disease type, chronic obstructive pulmonary disease is anticipated to account for maximum market share of 55% during the forecast period.
- Hospitals are projected to account for 71% market share by end-user, by end of 2033.
“Adoption of positive airway pressure devices and other product launches will bolster hypoventilation treatment market in the forecast period”- comments an FMI Analyst
Ask More About This Market’s Geographical Distribution Along With a Detailed Analysis of the Top Regions: https://www.futuremarketinsights.com/ask-question/rep-gb-16517
Competitive Landscape
The global Hypoventilation Management market is highly competitive a due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are: Accord Healthcare Limited, Avet Pharmaceuticals Inc, Nostrum Laboratories Inc, Lannett Co Inc, Strides Pharma Science Limited, X Gen Pharmaceuticals Inc, ResMed, Koninklijke Philips NV, Hikma Pharmaceuticals, Lincare Holdings
Some recent developments in this industry are:
- In June 2022, Verona Pharma, a pharmaceutical company announced the completion of the patient enrolment, with more than 800 subjects involved for its randomized ENHANCE-1 trial. The study will evaluate ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease, a type of hypoventilation disorder. It is a critical step for the phase III ENHANCE trial with top-line data expected by the end of the year 2022 and further data from ENHANCE-2 in the third quarter of 2022.
- In November 2021, AstraZeneca announced that it had sold rights to sell Tudorza, also known as Eklira abroad, and Duaklir to the Switzerland-based pharmaceutical company Covis Pharma Group for US$ 270 Mn. These products are indicated for the treatment of various types of hypoventilation disorders
- In May 2022, Alembic Pharmaceuticals Ltd, a pharmaceutical company, received final approval from the U.S. health regulator for its generic version of Arformoterol Tartrate inhalation solution indicated for long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. The approval by the U.S. Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution is for strength of 15 mcg (base)/2 mL unit-dose vial.
Get Exclusive Access to Segment-specific Details, Uncover Crucial Trends, Drivers, and Challenges: https://www.futuremarketinsights.com/checkout/16517
More Valuable Insights Available
Future Market Insights offers an unbiased analysis of the global Hypoventilation Management market, providing historical data for 2018 to 2022 and forecast statistics from 2023 to 2033.
To understand opportunities in the Hypoventilation Management market, the market is segmented on the basis of disease type (Chronic obstructive pulmonary disease, Obesity hypoventilation syndrome, Central alveolar hypoventilation, Neuromuscular disorders) by treatment (Oxygen therapy, Non-invasive mechanical ventilation, Drug therapy) by end-users (Hospitals, Specialty clinics, Home care) by region (North America, Latin America, Europe, South-Asia, East-Asia, Oceania, Middle East, and Africa)
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs
